NTRC is a precision medicine company dedicated to the development of new anti-cancer drugs. NTRC facilitates the development of novel therapies by providing immunotherapy assay development & screening; cancer cell line profiling; pharmacogenomics analysis; combination studies; and target residence time measurements for protein kinases. Assay read-outs for the cancer immunotherapy drug targets Arginase 1; IDO1; and TDO are supplied to clients globally. NTRC has internal drug discovery programs on TTK, IDO1 and TDO. For more information please visit www.ntrc.nl or contact info@ntrc.nl